Kim Forrest on Tariffs, AI Gear, and RFK Jr. on the Deep State

Market Volatility and Tariff Uncertainty

• 💡 The market is experiencing a measure of calm, but the day is considered "weird" due to light volume, potentially influenced by holidays like Passover and Easter.
• ⚠️ Confusion surrounds the carve-out of special exemptions for tariffs, particularly for industries like autos, leading to uncertainty about the long-term policy.
• 🎯 The complexity and interconnectedness of global product manufacturing are underestimated by the administration, as highlighted by Apple's embedded supply chain in China.
• 📈 Investors are advised to avoid fear and paralysis, recognizing that companies like Apple will adapt to higher prices and supply chain challenges to serve their customers.

Nvidia's AI Infrastructure Investment

• 🚀 Nvidia's announcement to produce up to $500 billion of AI gear in the US over four years is seen as a continuation of ongoing capital deployment, not entirely new news.
• 🧠 This move, including Blackwell production and supercomputer manufacturing, is comforting to US companies like Meta and Microsoft who rely on this infrastructure.
• ⚡ The decision to build manufacturing partnerships in the US is a smart risk-reduction strategy, mitigating delays experienced during COVID from relying on Taiwan.

RFK Jr.'s 'Deep State' Comments and FDA Restructuring

• 🗣️ RFK Jr. warned FDA staff about the "deep state" and CIA influence in an all-hands meeting, alongside controversial remarks about children with developmental disabilities.
• 📉 The HHS is undergoing a significant restructuring, expecting approximately 20,000 employees to depart, including about 3,500 from the FDA.
• 💊 The administration is probing sectoral tariffs on semiconductor and pharmaceutical imports, raising concerns about the global manufacturing supply chain for medicines.
• ⚠️ Historically, medicines have been spared from trade wars due to their impact on the average person, but the current probe could be impactful and lead to supply chain issues, as seen with past antibiotic shortages.